HONG KONG – In a first release of its kind, the CFDA posted two lists of drugs set for fast lane approval through the Center for Drug Evaluation (CDE). This is the first time drugs by foreign companies have been given priority since the launch of a pilot priority review process proposed earlier this year. The project is part of a strategy to clear a backlog of applications.